Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2009 - 2026)

Vertex Pharmaceuticals has reported Cash from Financing Activities for 18 years, with the latest figure at -$426.7 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 22.19% year-over-year to -$426.7 million in Q2 2026; TTM through Jun 2026 was -$2.2 billion, a 21.5% decrease from a year earlier, with the FY2025 full-year figure at -$2.3 billion, down 51.27% from the prior year.
• Cash from Financing Activities was -$426.7 million for Q2 2026 at Vertex Pharmaceuticals, up from -$538.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $47.7 million in Q2 2022, with the low at -$1.2 billion in Q3 2025.
• Average Cash from Financing Activities over 5 years is -$297.3 million, with a median of -$322.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities jumped 111.96% in 2022, then plunged 2172.83% in 2024.
• Over 5 years, Cash from Financing Activities stood at $40.2 million in 2022, then plunged by 398.01% to -$119.8 million in 2023, then tumbled by 226.63% to -$391.3 million in 2024, then surged by 80.27% to -$77.2 million in 2025, then slumped by 452.72% to -$426.7 million in 2026.
• The last three Cash from Financing Activities figures came in at -$426.7 million (Q2 2026), -$538.8 million (Q1 2026), and -$77.2 million (Q4 2025), per Business Quant data.